D9175
Dantrolene sodium salt
Ca2+ release from sarcoplasmic reticulum inhibitor, solid
Sinónimos:
1-[(5-(p-Nitrophenyl)furfurylidene)amino]hydantoin sodium salt
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
| Tamaño de envase | SKU | Disponibilidad | Precio |
|---|
Acerca de este artículo
Fórmula empírica (notación de Hill):
C14H9N4NaO5
Número CAS:
Peso molecular:
336.23
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Form:
solid
Quality level:
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
Dantrolene sodium salt,
form
solid
Quality Level
originator
JHP Pharmaceuticals
SMILES string
[Na+].[H]\C(=N/N1CC(=O)N=C1[O-])c2ccc(o2)-c3ccc(cc3)[N+]([O-])=O
InChI
1S/C14H10N4O5.Na/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22;/h1-7H,8H2,(H,16,19,20);/q;+1/p-1/b15-7+;
InChI key
KSRLIXGNPXAZHD-HAZZGOGXSA-M
Gene Information
human ... RYR1(6261), RYR3(6263)
Biochem/physiol Actions
Inhibitor of Ca2+ release from sarcoplasmic reticulum; muscle relaxant.
Features and Benefits
This compound is featured on the InsP3/Ryanodine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by JHP Pharmaceuticals. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
1 of 1
Este artículo | |||
|---|---|---|---|
| form solid | form - | form solid | form solid |
| Quality Level 200 | Quality Level 200 | Quality Level 100 | Quality Level 100 |
| originator JHP Pharmaceuticals | originator - | originator - | originator Novartis |
| Gene Information human ... RYR1(6261), RYR3(6263) | Gene Information - | Gene Information - | Gene Information - |
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Beth A McNally et al.
Frontiers in physiology, 12, 737291-737291 (2021-10-16)
Daily regulation of Ca2+ - and voltage-activated BK K+ channel activity is required for action potential rhythmicity in the suprachiasmatic nucleus (SCN) of the hypothalamus, the brain's circadian clock. In SCN neurons, BK activation is dependent upon multiple types of
Z H Németh et al.
Brain research bulletin, 46(3), 257-261 (1998-07-17)
Recent studies suggested that transmitters released from the sympathetic nerve terminals can modulate various inflammatory responses by occupation of receptors on immune cells. These neurotransmitters act via alteration of intracellular concentration of second messengers. For instance, intracellular calcium as a
Mohammed Ali Azam et al.
Heart rhythm O2, 2(6Part B), 733-741 (2022-01-07)
Doxorubicin (Dox) is a potent chemotherapeutic agent, but its usage is limited by dose-dependent cardiotoxicity. Intracellular calcium dysregulation has been reported to be involved in doxorubicin-induced cardiomyopathy (DICM). The cardioprotective role of RyR stabilizer dantrolene (Dan) on the calcium dynamics
Número de artículo de comercio global
| SKU | GTIN |
|---|---|
| D9175-100MG | 04061833590478 |
| D9175-250MG | 04061833590485 |
| D9175-1G | 04061826738443 |